Introduction
Lung cancer is a leading cause of cancer-related deaths worldwide with the highest incidence and mortality [
1]. The most effective treatment for patients at an early stage is surgical resection, but the relapse rate after surgery is high. In addition, numbers of patients are diagnosed at an advanced stage and the overall survival rate is poor [
2,
3]. Lung cancer is also a severely healthy burden in China, the incidence and mortality rate is still increasing with the accelerated progress of China’s industrial development and changes in lifestyle [
4‐
6]. Because of the poor survival of lung cancer patients in advanced stages, it is important to identify novel effective prognostic biomarkers and therapeutic strategies to improve the treatment of lung cancer.
MicroRNAs (miRNAs or miRs) are a class of small non-coding RNAs, approximately 22 nucleotides in length that negatively regulate gene expression at the post-transcriptional level through binding to the 3′- Untranslated Region(UTR) of target mRNAs [
7,
8]. Emerging evidence indicated that miRNAs play critical roles in the development and progression of various kinds of diseases, including cancers [
9‐
11]. Numerous studies have indicated that the aberrant expression of miRNAs is involved in various biological processes, including development, proliferation, migration, invasion, and apoptosis [
12‐
14]. Recent studies demonstrated that miRNAs such as miR-210, miR-577, and miR-141-3p are abnormal expressed in lung cancer pathogenesis [
15‐
17]. A recent study by Zhu et al. showed that ten miRNAs including miR-423-3p are increased in serum of lung cancer patients [
18]. However, the expression pattern of miR-423-3p in lung cancer tissues and biological role of miR-423-3p in lung cancer is still unclear.
In the present study, we aimed to investigate the expression and functional role of miR-423-3p in lung cancer and highlight its potential as a biomarker for lung cancer.
Materials and methods
Patients and tissue specimens
A total of 126 patients with lung cancer were included between January 2011 and December 2012 at Weifang Cancer Hospital in this study. The paired lung cancer tissue and matched adjacent normal tissue specimens (all were confirmed by at least two pathologists) were collected during surgery and snap frozen and stored at − 80 °C until RNA extraction. All the patients did not receive any treatment before surgery. 5-year follow-up information was enrolled to collect survival status by telephone. The clinicopathological characters of lung cancer patients were collected and listed in Table
1. All participants signed written informed consent in this study. The research was approved by the Ethics Committee of Weifang Cancer Hospital.
Table 1Correlation between miR-423-3p expression levels and clinical features in lung cancer patients
Age |
< 60 | 66 | 29 | 37 | 0.292 |
≥ 60 | 60 | 32 | 28 |
Gender |
Male | 75 | 37 | 38 | 0.802 |
Female | 51 | 24 | 27 |
Tumor size |
< 4 cm | 69 | 37 | 32 | 0.198 |
≥ 4 cm | 57 | 24 | 33 |
Differentiation |
Well + Moderate | 77 | 39 | 38 | 0.529 |
Poor | 49 | 22 | 27 |
Lymph node metastasis |
Negative | 67 | 39 | 28 | 0.019 |
Positive | 59 | 22 | 37 |
TNM stage |
I - II | 73 | 44 | 29 | 0.002 |
III - IV | 53 | 17 | 36 |
Cell lines and transfection
Four lung cancer cell lines (A549, H1299, HCC827, A427) and one human lung epithelial BEAS-2B cell line were purchased from Shanghai Cell Bank of the Chinese Academy of Sciences. All cells were cultured in RPMI 1640 medium (Gibco/Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) at 37 °C in a humidified atmosphere with 5% CO2. miR-423-3p mimic, mimic negative control (NC), miR-423-3p inhibitor, inhibitor NC (RiboBio, Guangzhou, China) were used for the overexpression and knockdown of miR-423-3p. Lung cancer cells were seeded onto a 6-well plate at 40–50% confluence before indicated transfection. Transfection of cells was conducted using Lipofectamine 2000 Reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. Untreated cells were used as control.
RNA extraction and qRT-PCR analysis
Total RNA was extracted from tissues or cells by using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s protocol. RNA concentrations were determined using the NanoDrop. Purified total RNA was reverse transcribed to complementary DNA (cDNA) using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Expression of miR-423-3p was measured by an SYBR Green I Real-Time PCR Kit (GenePharma, Shanghai, China) on an Applied Biosystems 7900 Real-Time PCR system (Applied Biosystems, Foster City, CA). Relative miR-423-3p expression was normalized to the expression of U6 and was quantified with the 2−ΔΔCt methods.
Cell proliferation assay
CCK-8 assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was used to assess the cell proliferation capacity following the manufacturer’s protocol. Transfected cells were seeded into 96-well culture plates (1 × 104 cells/well) at 37 °C in a humidified atmosphere with 5% CO2. Then CCK-8 reagents were added into cells at 0, 24, 48, and 72 h. After incubated for 1 h, the absorbance was measured using a microplate reader (Thermo Fisher Scientific) at 450 nm wavelength. The assay was repeated at least three times at each time point.
Cell migration and invasion assay
Transwell chambers (Multiskan MK3, Thermo, Waltham, MA, USA) with a pore size of 8 μm were used for cell migration and invasion assays. For the migration assay, no Matrigel was used in the top chamber, while for the invasion assay, Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was pre-coated in the top chamber. After 24 h of transfection, cells (5 × 104 cells/well) were seeded into the upper chamber with serum-free growth medium, and the lower chamber was filled with 500 μl medium with 10% FBS as a chemoattractant. Cells that were adhered to the lower membrane were fixed in 3.7% formaldehyde for 5 min and stained with 0.1% crystal violet for 15 min. Stained cells were counted under a microscope.
Statistical analysis
SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 5.0 software (GraphPad Software, Inc., Chicago, USA) were used for statistical analysis. Data are presented as mean ± standard deviation (SD). χ2 test, Student’s t-test or one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test was applied to evaluate statistical differences. Kaplan-Meier analysis and Cox regression analysis were used to determine the prognostic significance of miR-423-3p. Differences were considered statistically significant when P < 0.05.
Discussion
In this study, miR-423-3p was upregulated in lung cancer tissues compared with that in adjacent normal tissues, and in lung cancer cells compared with normal lung epithelial BEAS-2B cell. Overexpression of miR-423-3p in lung cancer tissues was identified to be significantly associated with lymph node metastasis, TNM stage, and poor prognosis of lung cancer patients. Furthermore, miR-423-3p was revealed to function as an oncogene in lung cancer by promoting cell proliferation, migration, and invasion. Taken together, the present results suggest that miR-423-3p functions as an oncogene in lung cancer and may potentially be utilized as a prognostic indicator.
Although substantive progress has been made in diagnosis and targeted therapy for lung cancer, the 5-year overall survival rate of lung cancer is still fairly low [
19,
20]. Searching for effective biomarkers for early diagnosis, prognosis, and therapeutic targets for the treatment of lung cancer is still essential. Increasing studies have identified that molecular markers including miRNAs play an important role in the diagnosis and/or prognosis in various cancers [
21‐
24]. For instance, miR-23a as one of the most extensively studied miRNAs in various cancers plays an essential role in the application of cancer diagnosis, prognosis, and treatment [
23]. A study indicated that miR-145 was significantly downregulated in hepatocellular carcinoma tissues and had prognostic value in hepatocellular carcinoma [
24]. These studies demonstrated that miRNAs have clinical significance for the treatment of cancers.
Some miRNAs have been identified as an oncogene or suppressor gene and involved in the progression of lung cancer [
25]. For instance, miR-1269a acts as an onco-miRNA in non-small cell lung cancer (NSCLC) and promotes cancer cell growth by downregulating the expression of SOX6 [
26]. miR-140-3p was indicated as a tumor suppressor and had the prognostic and therapeutic role in squamous cell lung cancer [
27]. The expression of miR-218 was found significantly downregulated in lung cancer tissues and it acted as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlated with poor prognosis [
28]. miR-423-3p, located on chromosome 17q11, was reported as an oncogene in several types of cancers, such as breast cancer, head and neck squamous cell carcinoma, and endometrial cancer [
29‐
31]. In the present study, we examined the expression of miR-423-3p and explored its potential role in lung cancer. The results suggested that miR-423-3p was upregulated in lung cancer tissues and cell lines. Moreover, we found miR-423-3p was associated with lymph node metastasis and TNM stage. These results suggested that miR-423-3p may be an oncogene and is involved in the development and progression of lung cancer, which is consistent with other previous studies.
To explore the clinical prognostic significance of miR-423-3p in lung cancer, we performed Kaplan-Meier curve and Cox regression analyses according to the clinical features and overall survival information of lung cancer patients. The results indicated that lung cancer patients with tumors expressing high profiles of miR-423-3p exhibit poorer survival outcome. And miR-423-3p is an independent prognostic factor for overall survival of lung cancer patients. These results indicated that miR-423-3p is an independent prognostic biomarker for lung cancer.
Previous studies also demonstrated that miR-423-3p is closely associated with tumor progression of several types of cancers [
32‐
35]. For instance, in gastric cancer, miR-423-3p is upregulated in gastric cancer tissues and promotes cell proliferation, migration, and invasion in cell lines and animal models [
32]. To explore the biological function of miR-423-3p in the progression of lung cancer, we investigated the effects of miR-423-3p on cell proliferation, migration, and invasion of lung cancer cell lines. We found that overexpression of miR-423-3p significantly promoted lung cancer cell proliferation, migration, and invasion, while inhibition of miR-423-3p suppressed cell proliferation, migration, and invasion, compared with controls. In addition, a study by Li et al. showed miR-423-3p is significantly upregulated in colorectal cancer tissues and enhances cell growth through inhibition of p21Cip1/Waf1 in colorectal cancer [
33]. Another study by Guan et al. demonstrated miR-423-3p plays an important oncogenic role in laryngeal carcinoma progression via modulation of AdipoR2 [
34]. A recent study showed that overexpression of AdipoR1 and AdipoR2 inhibited migration and invasion in NSCLC [
36]. In our current study, we observed that miR-423-3p is involved in the development and progression of lung cancer. Therefore, We speculate miR-423-3p may also function as an oncogene role in lung cancer progression through regulating expression of AdipoR2. The detailed molecular mechanisms of miR-423-3p in lung cancer will be investigated in further investigation.
Taken together, this study indicated miR-423-3p is upregulated in lung cancer and promotes cell proliferation, migration, and invasion. Our data suggested that miR-423-3p functions as an oncogene and may act as a prognostic biomarker and therapeutic target for lung cancer.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.